Global hemotransmissive infections testing demand is anticipated to be valued at US$ 2 Billion in 2022, forecast to grow at a CAGR of 11.61% to be valued at US$ 6 Billion from 2022 to 2032.
| Report Attribute | Details |
| Estimated Base Year Value (2021) | US$ 1.5 Billion |
| Expected Market Value (2022) | US$ 2 Billion |
| Anticipated Forecast Value (2032) | US$ 6 Billion |
| Projected Growth Rate (2022-2032) | 11.61% CAGR |
Hemotransmissive infections are infections that spread through blood when an infected person comes into contact with another infected person. The most common diseases spread through blood are hepatitis C, hepatitis B, and the human immunodeficiency virus (HIV). It is critical to diagnose these diseases as soon as possible in order to treat or manage them.
The hemotransmissive infections testing market is undergoing regulatory changes from the government of the respective region or country, such as in December 2018, the government of the United States updated law regarding age and consent of diagnosis, i.e. minors aged 15 to 18 years can now be tested without the consent of their legal guardian or parents, which can increase the possibility of early diagnosis in patients under the age of 18 years.
According to the European Centre for Disease Prevention and Control and WHO, HIV infections have increased significantly in Eastern Europe, with over 130,000 people infected in 2016, whereas HIV infection has decreased by nearly 20.0% in Western Europe. Similarly, as the prevalence of hepatitis C and hepatitis B rises, hemotransmissive infections testing can play an important role in early diagnosis.
The rising prevalence of HIV in the developing world, owing to a lack of knowledge about preventive measures, is expected to fuel the growth of the hemotransmissive infections testing market. Despite the fact that the prevalence of HIV is rising, government initiatives such as free HIV testing are expected to drive the growth of the hemotransmissive infections testing market.
According to the WHO, there are approximately 71.0 million people worldwide who have hepatitis C, and 399,000 people die from it each year. The general public's growing awareness of the symptoms and diagnostic measures is expected to fuel the growth of the hemotransmissive infections testing market. Similarly, hepatitis B can be fatal if not detected in time, indicating that the hemotransmissive infections testing market has significant revenue generation potential.
Various initiatives by the government, non-profit organizations, and healthcare professionals can improve the timely diagnosis of these diseases with hemotransmissive infections testing kits, thereby driving the hemotransmissive infections testing market growth.
The high cost of hemotransmissive infections testing may stymie the hemotransmissive infections testing market's potential growth.
The Asia-Pacific hemotransmissive infections testing market is growing as patient awareness grows and various government initiatives for early diagnosis of hemotransmissive infections are implemented.
According to Future Market Insights, Because of the rising prevalence of hemotransmissive infections, Europe's hemotransmissive infections testing market is expected to be the second most lucrative.
AO Vector-Best, Atlas Medical Uk, Launch Diagnostics, Creative Diagnostics, Shanghai Chemtron Biotech, Oscar Medicare, MyBioSource.com, ABON Biopharm (Hangzhou), Bio-Rad Laboratories, Trinity Biotech Manufacturing Ltd, and others are the key players in the global hemotransmissive infections testing market.
Attributed to the presence of such high number of participants, the market is highly competitive.
| Report Attribute | Details |
| Growth Rate | CAGR of 11.61% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
Test Type:
Indication:
End Userv
Region:
FMI projects the global Hemotransmissive Infections Testing market to expand at an 11.61% value CAGR by 2032
Asia Pacific is expected to be the most opportunistic Hemotransmissive Infections Testing market.
AO Vector-Best, Atlas Medical Uk, Launch Diagnostics and Creative Diagnostics, are some prominent Hemotransmissive Infections Testing manufacturers
Explore Similar Insights
Hemotransmissive Infections Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
